Clinical Trial Update: Combination of Basiliximab and Pegaspargase in the Treatment of ENKTCL [Phase 2]

View source ↗

Summary

Phase 2 trial update exploring the combination of Basiliximab and Pegaspargase for Extranodal NK/T-cell Lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extranodal Nk T-cell Lymphoma

Drugs mentioned

• Basiliximab (basiliximab)
• Pegaspargase (pegaspargase)

Snippet

Sponsor: Beijing Tongren Hospital | Conditions: Extranodal NK/T-cell Lymphoma | Phase 2 | Status: UNKNOWN